WEST CHESTER, Ohio--(EON: Enhanced Online News)--AtriCure, Inc. (Nasdaq: ATRC), a leading atrial fibrillation (Afib) solutions partner, has announced a significant multi-year strategic investment in clinical trial and educational initiatives aimed at reducing the global Afib epidemic. The announcement coincides with Atrial Fibrillation Awareness Month, which was created to bring attention to this growing public health issue. Afib is associated with significant morbidity and mortality from stroke and heart failure, as well as impaired quality of life.
“The ACT Against Afib campaign is an excellent way to spread the word about the risks and treatment options, and we encourage physicians to become involved through the ACT campaign.”
"This year, we reassert our aggressive efforts to collaborate with leading electrophysiologists, cardiologists, and surgeons to find long-lasting, evidenced-based solutions that are proven through rigorous clinical trials,” said Michael Carrel, president and CEO of AtriCure. “One in four Americans aged 40 or older will be diagnosed with Afib in their lifetime. Without an urgent focus on raising awareness and delivering effective and durable Afib solutions, the physical and emotional impact on families, and the financial impact on society, will be enormous. Our goal is to favorably impact the lives of 250,000 patients and their family members by the end of the decade through greater awareness and treatment.”
To accomplish this goal AtriCure is making significant investments in clinical science and physician education initiatives. The ABLATE PAS study is the largest and most rigorous multi-centered surgical ablation study ever attempted. It will build upon the success demonstrated in AtriCure’s landmark FDA trial and further support the durability of the Synergy Ablation System for the treatment of persistent and long-standing persistent Afib. AtriCure’s Synergy Ablation System is currently the only FDA-approved surgical device for the treatment of Afib. As of this month, the ABLATE PAS study passed the halfway point in patient enrollment and will continue to follow patients for three years post procedure. Additionally, in an effort to ensure standardization of the Maze IV procedure to achieve the highest possible quality outcomes, AtriCure has provided in-depth surgeon education to over 1,000 surgeons.
In recognition that patient awareness is a key aspect of making an impact on this healthcare epidemic, AtriCure has developed a new campaign focused on Afib risk awareness and treatment options entitled, “ACT Against Afib”. “ACT” is an acronym for the three steps involved in patient awareness and understanding treatment options: Assess your risk, Consult with your doctor, and Treat your Afib. The campaign will include advertising, press releases to the public, a website for patients and physicians, media kits for hospitals and advocacy groups to partner on the campaign and special events throughout the year.
“As a leader in the clinical research and treatment of Afib, we’re all-too-familiar with its devastating effects, and the near epidemic levels of people suffering from Afib. Our goal is to partner with physicians to provide superior treatment options as well as to create greater public awareness about this progressive disease and the options available,” according to Sydney Gaynor, MD, cardiothoracic surgeon and medical director at AtriCure. Further, “The ACT Against Afib campaign is an excellent way to spread the word about the risks and treatment options, and we encourage physicians to become involved through the ACT campaign.”
About AtriCure, Inc.
AtriCure, Inc. is a leading atrial fibrillation solutions partner, providing innovative products, professional education and support for clinical science to reduce the economic and social burden of atrial fibrillation. AtriCure's Synergy Ablation System is the first and only device approved by the Food and Drug Administration (FDA) for the surgical treatment of Persistent and Longstanding Persistent forms of Afib in patients undergoing certain open heart procedures concomitantly (simultaneously). AtriCure's AtriClip™ Left Atrial Appendage (LAA) occlusion device is the most widely implanted device for LAA management worldwide. Afib affects more than two million people worldwide and is estimated to cost more than $6.5 billion annually in healthcare expenses. The number affected by Afib is expected to grow to 12 million by 2050.
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements that address activities, events or developments that AtriCure expects, believes or anticipates will or may occur in the future, such as earnings estimates, other predictions of financial performance, launches by AtriCure of new products and market acceptance of AtriCure’s products. Forward-looking statements are based on AtriCure’s experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances and are subject to numerous risks and uncertainties, many of which are beyond AtriCure’s control. These risks and uncertainties include the rate and degree of market acceptance of AtriCure’s products, AtriCure’s ability to develop and market new and enhanced products, the timing of and ability to obtain and maintain regulatory clearances and approvals for its products, the timing of and ability to obtain reimbursement of procedures utilizing AtriCure’s products, competition from existing and new products and procedures or AtriCure’s ability to effectively react to other risks and uncertainties described from time to time in AtriCure’s SEC filings, such as fluctuation of quarterly financial results, reliance on third party manufacturers and suppliers, litigation or other proceedings, government regulation and stock price volatility. AtriCure does not guarantee any forward-looking statement, and actual results may differ materially from those projected. AtriCure undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.